ArticleJournal of advanced research2026
Discovery of natural RORγt inhibitor using machine learning, virtual screening, and in vivo validation.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current and Emerging Therapies Targeting the IL-23/IL-17 Axis in Psoriasis.Biomolecules & therapeutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRetinoic acid receptor-related orphan receptor gamma t (RORγt) is a crucial transcription factor regulating Th17 cells, which secrete the cytokine IL-17. RORγt inhibitors are regarded as a therapeutic modality in a wide range of autoimmunity including psoriasis.
objectivesThe objective of the study is to investigate novel RORγt inhibitors from natural products (NPs), combining machine learning (ML)-based virtual screening, chemotaxonomic analysis, molecular docking, and molecular dynamics simulations, and biological validation.
methodsThis study employed an integrated approach combining ML-based ligand-based screening, docking study, molecular simulation, and chemotaxonomic analysis to identify RORγt inhibitors from NPs.
resultsML ensemble models predicted potential RORγt inhibitors from an NP library; subsequent chemotaxonomic classification of top-ranked hits prioritized protoberberine alkaloids. Six protoberberine alkaloids, which are predicted to bind RORγt via docking studies, were selected for experimental validation. Among them, berberine (Ber) and coptisine (Cop) potently inhibited Th17 differentiation in vitro. Surface plasmon resonance analysis demonstrated that both Ber and Cop directly bind to RORγt, with Cop exhibiting a stronger affinity for RORγt than Ber. Moreover, Cop demonstrated therapeutic efficacy in a preclinical mouse model of psoriasis. These results validate an integrated workflow, combining ML, chemotaxonomy, and experimental testing in vitro and in vivo, for the efficient discovery of novel RORγt inhibitors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.